JFG
IMVT icon

Jefferies Financial Group’s Immunovant IMVT Stock Holding History

Jefferies Financial Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,574
Closed -$909K – 1807
2023
Q4 		$909K Buy
+21,574
New +$794K 0.01% 998

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Jefferies Financial Group's IMVT Position: Q1 2024 in Review

Jefferies Financial Group sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 21,574 shares — an estimated $909K sold.

Jefferies Financial Group first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $909K in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

  • Jefferies Financial Group reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
  • Jefferies Financial Group sold 21,574 Immunovant shares in Q1 2024, an estimated $909K.
  • Jefferies Financial Group first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
  • Jefferies Financial Group's Immunovant position peaked at $909K in Q4 2023.
  • 209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on Jefferies Financial Group's 13F filing for Q1 2024, filed 13 May 2024.